Select publications

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Colombat P et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001;97(1):101-6. Abstract

Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26(5 Suppl 14):88-96. Abstract

Czuczman MS et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Proc ASH 2003;Abstract 1493.

Czuczman MS et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17(1):268-76. Abstract

Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract

Goy A et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). Proc ASCO 2004;Abstract 6581.

Hainsworth JD et al. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin’s lymphoma: Phase II trial. Clin Lymphoma 2003;4(1):36-42. Abstract

Hainsworth JD et al. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin’s lymphoma (NHL): Long-term follow-up of a Minnie Pearl Cancer Research Network phase II Trial. Proc ASH 2003;Abstract 1496.

Hainsworth JD et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002;20(20):4261-7. Abstract

Hainsworth JD et al. Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin’s lymphoma (NHL) responding to singleagent rituximab: A randomized trial of the Minnie Pearl Cancer Research Network. Proc ASH 2003;Abstract 231.

Hainsworth JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21(9):1746-51. Abstract

Hiddemann W et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASH 2003;Abstract 352.

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502. Abstract

Kwak LW et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327(17):1209-15. Abstract

Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma. Proc ASH 2003;Abstract 87.

O’Connor OA et al. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Proc ASCO 2004;Abstract 6581.

Pfreundschuh MG et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. Proc ASCO 2004;Abstract 6500. Abstract

Press OW et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102(5):1606-12. Abstract

Rambaldi A et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99(3):856-62. Abstract

Seymour JF et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003;21(11):2115-22. Abstract

Shipley DL et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Yibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. Proc ASCO 2004;Abstract 6519.

Vose JM et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001;19(2):389-97. Abstract